Is BPC-157 Legal in Oregon? Federal Rules, Pharmacy Access, and What Patients Need to Know

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

The short answer for Oregon

BPC-157 is not an FDA-approved drug. FDA's July 2026 review found no approved product containing it in any country it searched, there is no US Pharmacopeia or National Formulary monograph for it, and websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use' [1].

The Oregon Board of Pharmacy lists ORS Chapter 689 and OAR Chapter 855 as the state's pharmacy statutes and rules; the Board's page does not mention BPC-157 [4]. Federal compounding law applies as well: compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [5].

What FDA says about the peptide

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1].

How it works in people is not established. FDA says its molecular targets have not been identified, its mechanisms 'remain poorly understood', and dose-response relationships for the reported protective effects were not established. The reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1].

On safety, FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. Its search of the adverse-event database through December 4, 2025 found 3 reports, all involving injectable product: injection-site redness and swelling for 9 days in a patient who also used compounded thymosin; shortness of breath that led to an emergency room visit; and widespread skin and gum darkening that recurred when the person was exposed again to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused these [1].

Animal signals FDA noted: in 28-day intramuscular studies BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1]. FDA found no human pharmacokinetic data for the peptide given by mouth, subcutaneously, nasally or on the skin, and after rectal enemas in two early studies it was mostly not detectable in blood [1].

Where BPC-157 sits on FDA's compounding lists

Three separate lists matter.

The safety-risk category. BPC-157 was in category 2, FDA's group for bulk substances that may present significant safety risks, from September 2023 until April 22, 2026. It now sits in a separate 'nominated but withdrawn' table because the groups that nominated it withdrew. That page still carries FDA's stated concerns: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', may have peptide-related impurity and characterization problems, and FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [6]. Removal from category 2 was not a finding of safety [6].

The nominated bulks list for state-licensed pharmacies. On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, BPC-157 is in none of the three categories [2]. Category 1 is the group FDA says it generally will not act against compounders for, if conditions are met, so that policy does not cover BPC-157 [2].

The outsourcing facility list. BPC-157 is not on FDA's bulk substances list for outsourcing facilities, updated March 21, 2025 [8].

FDA's own reviewers recommended against adding BPC-157 to the pharmacy bulks list in the July 2026 briefing. Their reasons: it is not well characterized chemically, little is known about its safety and immunogenicity, there is insufficient evidence that it works for ulcerative colitis (the use FDA evaluated), and several FDA-approved drugs already treat ulcerative colitis [1].

On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the list, against staff's recommendation [7]. Advisory committees make non-binding recommendations. BPC-157 is not on the list, and adding it requires formal rulemaking: a proposed rule, a public comment period and a final rule [7][10].

The October 2026 draft HHS policy

On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for six peptides, BPC-157 among them, scheduled for Federal Register publication on October 30, 2026 with public comments open for two weeks after publication [3]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3].

For BPC-157, the draft conditions are: the acetate form only; subcutaneous, intramuscular, oral or topical routes (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard; a label reading 'This is a compounded drug product. Not for resale.'; a patient-specific prescription; reporting of serious adverse events and quality problems to FDA MedWatch; only an FDA 510(k)-cleared syringe as a co-packaged device; and documentation of adequate bioavailability for oral forms [10].

This draft is not an approval and does not put BPC-157 on any FDA list. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and that HHS may revisit it, for example if a safety signal or product quality issue appears [3]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [3].

Oregon: what the state rules cover

ORS Chapter 689 is the Oregon pharmacy statute chapter (the Pharmacy Practice Act) and OAR Chapter 855 holds the state's administrative rules for pharmacy, as listed by the Oregon Board of Pharmacy [4]. The Board's page does not mention BPC-157 [4].

On the federal side, FDA describes the compounding exemption as carrying several conditions, including a valid patient-specific prescription [5]. For BPC-157, FDA's nominated bulks list for state-licensed pharmacies places it in none of the three categories [2], and it is not on the outsourcing facility list [8].

What the human studies show

A 2026 systematic review searched to June 1, 2026 and found 3 human studies of BPC-157 in orthopaedic and regenerative use, 30 patients in total. All three were judged of poor methodological quality, certainty of evidence was rated very low, and the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [11].

Those three studies:

• Knee pain. A retrospective chart review at one Florida clinic, 17 patients, 16 reached by phone; 11 of the 12 who received BPC-157 alone (91.6%) reported significant improvement. There was no control group and no validated outcome tools, and patients recalled their results [12].
• Interstitial cystitis. 12 women aged 39 to 76, none of whom had responded to pentosan polysulfate, received a total of 10 mg injected around the bladder wall in one procedure; 10 reported complete symptom resolution and 2 reported about 80% success. Single arm, no placebo, patient-rated [13].
• Intravenous safety. 2 adults received 10 mg on day 1 and 20 mg on day 2, with no measurable change in the heart, liver, kidney, thyroid or glucose markers tested and no reported side effects. Two participants cannot establish safety [14].

FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or on the skin [1].

Sport: WADA prohibits it

WADA's Prohibited List names BPC-157 in S0, non-approved substances, a class covering substances with no current approval by any governmental regulatory health authority for human therapeutic use; the class says it includes 'but not limited to BPC-157'. It is prohibited at all times, in and out of competition, and the 2026 List has been in force since January 1, 2026 [9]. WADA first named BPC-157 as an example under S0 in the 2022 List, and it stays named in the 2027 List, approved September 10, 2026 and in force January 1, 2027 [15][16].